BioWorld tracked 152 clinical trial readouts across phases I through III in February 2026, up from 144 in January but down from 215 in December. Of those, 20 phase III trials reported positive results, while one failed to meet key endpoints. By phase, February’s updates consisted of 50 from phase I, 46 from phase II and 57 from phase III.

With all the focus of late on the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP), the FDA’s 30-plus advisory committees have been flying under the radar, especially since many of them haven’t met for a few years now.

The debated and ultimately stock-denting March 26 news from Wave Life Sciences Inc. pushed into the spotlight other firms working with INHBE and activin E.

In a small Houston clinic, more than a decade ago, patients with advanced cancer were receiving treatments that used radioactive molecules to seek out tumors and destroy them from within using an approach that would eventually help reshape oncology.

The BioWorld Drug Developers Index (BDDI) rose 6.42% in the first two months of 2026, outpacing both the Nasdaq Biotechnology Index (NBI) and the Dow Jones Industrial Average (DJIA).

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to move toward success – both at the level of individual companies and for indications as a whole.

The first day of Bio-Europe Spring, being held for the first time in Lisbon this year, featured panels on the partnering landscape in specific indications, as well as a more general panel on “Piecing Together the Therapeutic Landscape with Analyst Insights.” One theme of the panel was that by and large, large companies are looking for deals with companies that fit with their existing programs – but that such a fit can come in many forms.